Matthew Gray

Duke Heart Failure Research

[Daxor @DaxorBVA]

#BreakingNews! Daxor’s next generation #BVA device changes the game by delivering even faster, precise blood volume data —from the hospital to the outpatient clinic. Read more. https://t.co/Evz2ysw8LX
@NasdaqExchange
@CoreIR_
$DXR

[Marat Fudim, MD MHS @FudimMarat]

🚨New Study Alert

First two patients randomized into the Splanchnic X trial @DukeHeartCenter

We study the safety and efficacy in splanchnic nerve ablation (aka SAVM therapy) in HFrEF

This is the first RCT in HFrEF

https://t.co/NLurafGSIw

@manesh_patelMD @NIH @AxonTherapies

[HF Collaboratory @hfcollaboratory]

We’d like to start announcing winners of our newest award, “Excellence in SBR” for sites, PIs, & SCs who consistently demonstrate excellence in their work and received a previous SBR awards

🏅Congrats to the @DukeHeartCenter team: @robmentz @jamesmattgray & Lacey Taylor!

[Duke Clinical Research Institute @DCRINews]

In a new review for @JACCJournals, DCRI Fellow @vkittipibul and @robmentz discuss the benefits of SGLT2i, the associated risk of GU infections, and practice considerations for patients with cardiovascular disease: https://t.co/zx9xbK9xU4

[Duke Department of Medicine @dukemedicine]

Bob Keegan's passion for team building has reached new heights with a transformative gift. His philanthropy is empowering the Duke Heart Precision and Innovation Collaboratory, spearheaded by Dr. Manesh Patel, to revolutionize cardiovascular care. https://t.co/qAPGdv2K3e

[Daxor @DaxorBVA]

#Webinar: Experts share how #BVA significantly elevates the effectiveness of conventional care. Register here: https://t.co/STQIWW7PEp
@ShreeMulay
@jljefferiesmd
#CardioTwitter
#nephrology

[Marat Fudim, MD MHS @FudimMarat]

🔖Recap of #THT2024
Presentation on the SCALE-HF 1 trial

Remote monitoring is a competitive space

The ideal gold-standard is invasive monitoring but what we use in clinical practice day to day are
🚨Scales🚨

We tested the "Cardiac Scale" and congestion index
@DCRINews

[Daxor @DaxorBVA]

#PressRelease: New study shows the benefits of #BVA in optimizing individualized therapy for #heartfailure patients with impaired renal function.

Read full story here: https://t.co/1gpCFyIxqZ

@NasdaqExchange
$DXR
#THT2024
@DCRINews
@vkittipibul

[NEJM @NEJM]

Patients with evidence of microplastics and nanoplastics in carotid artery plaque, as compared with patients without, had a greater risk of adverse cardiovascular events at 34 months of follow-up. Read the full article: https://t.co/BUsdzHMcdb

[Marat Fudim, MD MHS @FudimMarat]

Duke Heart Failure Symposium on May 4th.

✅Agenda and sign up link below:

https://t.co/gWbtFvmDYT

[Duke Clinical Research Institute @DCRINews]

The REBALANCE-HF trial, presented by @FudimMarat, headlined this year’s @HFSA Annual Scientific Meeting late-breaking session. Watch as Marat joins @SJGreene_md and @mvaduganathan for an episode of their Don’t Miss a Beat podcast to discuss the trial: https://t.co/sE5NJ7wzuu

[Marat Fudim, MD MHS @FudimMarat]

#HERMES investigator meeting @HFSA. Exciting agenda and special guest @lamcardio

Ready to squash inflammation in HFpEF.

@udi_fainberg @Jcontreras75 @novonordiskus

[Pat McAfee @PatMcAfeeShow]

This is a BEAUTIFUL place..

These are FOOTBALL PEOPLE

#CollegeGameDay

[Duke Football @DukeFOOTBALL]

Time to talk 😈

[Daxor @DaxorBVA]

#PressRelease: #BVA will be featured during a scientific session panel discussion with leading experts titled Managing Congestion: Targeting Pressure vs. Volume.
Read full story here: https://t.co/YL9CpcBJpc
@HFSA @Nasdaq $DXR #HFSA2023

[Jacob Niall Schroder @JacobNiall]

People say temp MCS used to game 🫀allocation. Thus far this week at @DukeHeartCenter:

5 🫀tx
All status 4s
Match sequences 135, 189, 44, 49, 35
(National ave is 3!!!)
4/5 all other centers coded out.

All patients doing well

@DukeHrtFailure expanding 🫀donor pool!

Rule 76…

[Marat Fudim, MD MHS @FudimMarat]

The global expert panel meeting is a wrap. Collegues/friends from all over the world have joined to discuss rationale, enrollment, retention, diversity/equity and inclusion for the #HERMES trial
We test an IL-6 inhibitor Ziltivekimab in #HFpEF @MajaCikes

#stop_inflammation

[Robert Mentz, MD @robmentz]

HEART-FID (FCM in HFrEF + ID) on behalf of huge team #ESCCongress @escardio
FCM safe w modest benefit in hierarchical endpt (mortality, HF hosp, 6MWD)-Didn't meet pre-specified level of stat signif
https://t.co/cz3RUFYj9q
Pooled FCM data to contextualize
https://t.co/sR2eerpijT

[Cardiology Today @CardiologyToday]

Hot off the press! Brand-new #HealioExclusive on #hearttransplant advances, outcomes, remaining challenges and more.

Thanks to @_adevore @sethhollander @minnowwalsh and others for sharing their thoughts with @GoHealio
https://t.co/rc6eTtUwMJ

[Oren Gottfried, MD @OGdukeneurosurg]

Wow, look at this cool device plow through the artery and morselize & remove atherosclerotic buildup. Source: Rotarex